[go: up one dir, main page]

DK1877090T3 - Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf - Google Patents

Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf

Info

Publication number
DK1877090T3
DK1877090T3 DK06770019.5T DK06770019T DK1877090T3 DK 1877090 T3 DK1877090 T3 DK 1877090T3 DK 06770019 T DK06770019 T DK 06770019T DK 1877090 T3 DK1877090 T3 DK 1877090T3
Authority
DK
Denmark
Prior art keywords
trimed
methods
fusion protein
immunoglobulin fusion
immunoglobulin
Prior art date
Application number
DK06770019.5T
Other languages
English (en)
Inventor
Andrew D Weinberg
Nicholas P Morris
Carmen Peters
Original Assignee
Providence Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Providence Health System filed Critical Providence Health System
Application granted granted Critical
Publication of DK1877090T3 publication Critical patent/DK1877090T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK06770019.5T 2005-05-06 2006-05-04 Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf DK1877090T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67842005P 2005-05-06 2005-05-06
PCT/US2006/017285 WO2006121810A2 (en) 2005-05-06 2006-05-04 Trimeric ox40-immunoglobulin fusion protein and methods of use

Publications (1)

Publication Number Publication Date
DK1877090T3 true DK1877090T3 (da) 2014-04-14

Family

ID=37397109

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13165713.2T DK2650020T3 (da) 2005-05-06 2006-05-04 Trimerisk OX40-immunglobulin-fusionsprotein og fremgangsmåder til anvendelser.
DK06770019.5T DK1877090T3 (da) 2005-05-06 2006-05-04 Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK13165713.2T DK2650020T3 (da) 2005-05-06 2006-05-04 Trimerisk OX40-immunglobulin-fusionsprotein og fremgangsmåder til anvendelser.

Country Status (13)

Country Link
US (2) US20060280728A1 (da)
EP (2) EP1877090B1 (da)
AU (1) AU2006244497B2 (da)
CA (1) CA2606809C (da)
CY (2) CY1119342T1 (da)
DK (2) DK2650020T3 (da)
ES (2) ES2605380T3 (da)
HU (1) HUE029789T2 (da)
LT (1) LT2650020T (da)
PL (2) PL1877090T3 (da)
PT (2) PT2650020T (da)
SI (2) SI1877090T1 (da)
WO (1) WO2006121810A2 (da)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312700B1 (en) * 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
DK2806883T3 (da) 2012-01-25 2019-07-22 Dnatrix Inc Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation
EP2812022B1 (en) 2012-02-06 2019-06-26 Providence Health & Services - Oregon Method of monitoring cancer treatment using ox40 agonists
US10329350B2 (en) 2012-12-26 2019-06-25 Industrial Technology Research Institute Method for producing a multivalent fab fragment with collagen-like peptide
WO2014110368A1 (en) 2013-01-11 2014-07-17 The California Institute For Biomedical Research Bovine fusion antibodies
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
WO2014121099A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
WO2015116178A1 (en) * 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
ES2649180T3 (es) 2013-02-22 2018-01-10 Curevac Ag Combinación de vacunación e inhibición de la ruta PD-1
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
DK2970427T3 (da) 2013-03-15 2020-03-09 Geoffrey W Stone Sammensætning bestående af antigen bundet til en tnf-superfamilieligand
KR102361237B1 (ko) * 2013-07-11 2022-02-09 더 스크립스 리서치 인스티튜트 코일드 코일 면역글로불린 융합 단백질 및 이것의 조성물
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
CA2931322A1 (en) 2013-11-22 2015-05-28 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
EP3590529A1 (en) 2014-03-12 2020-01-08 CureVac AG Combination of vaccination and ox40 agonists
MX2016012779A (es) 2014-03-31 2017-04-27 Genentech Inc Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
SG11201608181YA (en) 2014-04-03 2016-10-28 Augusta University Res Inst Inc Methods for enhancing the efficacy of a tumor-directed immune response
US9718870B2 (en) 2014-05-29 2017-08-01 Medimmune, Llc OX40L fusion proteins and uses thereof
EP4140485A1 (en) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
HUE043227T2 (hu) 2014-10-24 2019-08-28 Astrazeneca Ab Kombináció
SG11201703448QA (en) 2014-11-03 2017-05-30 Genentech Inc Assays for detecting t cell immune subsets and methods of use thereof
RU2017119231A (ru) 2014-11-03 2018-12-06 Дженентек, Инк. Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40
WO2016073282A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
US10046047B2 (en) 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
JP6996979B2 (ja) 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
EP3280736A1 (en) 2015-04-07 2018-02-14 F. Hoffmann-La Roche AG Antigen binding complex having agonistic activity and methods of use
TWI716405B (zh) 2015-05-07 2021-01-21 美商艾吉納斯公司 抗ox40抗體及其使用方法
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
KR20180033588A (ko) * 2015-08-12 2018-04-03 메디뮨 리미티드 Ｇｉｔｒｌ 융합 단백질 및 그의 용도
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
US20180263985A1 (en) 2015-09-15 2018-09-20 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
MY186016A (en) 2015-09-25 2021-06-14 Genentech Inc Anti-tigit antibodies and methods of use
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MA43017A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
EP3383430A4 (en) 2015-12-02 2019-12-18 Agenus Inc. ANTIBODIES AND METHOD FOR USE THEREOF
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
CA3010987A1 (en) 2016-01-08 2017-07-13 Replimune Limited Oncolytic herpes simplex virus type 1 strain
US20170198051A1 (en) * 2016-01-11 2017-07-13 Inhibrx Lp Multivalent and multispecific ox40-binding fusion proteins
PL3426271T3 (pl) 2016-03-10 2025-11-24 Cg Oncology, Inc. Sposoby leczenia guzów litych terapią skojarzoną
DE102016105069A1 (de) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antivirale Immuntherapie durch Membranrezeptorligation
EP3231813A1 (en) * 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
EP3243836A1 (en) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
US20200121719A1 (en) 2017-01-06 2020-04-23 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
JP2020516590A (ja) 2017-04-14 2020-06-11 コールド ジェネシス， インコーポレイテッド 膀胱癌の治療方法
US11377490B2 (en) * 2017-05-31 2022-07-05 Sichuan Clover Biopharmaceuticals, Inc Method for treating cancer using disulfide-linked trimeric 4-1BBL
US11819517B2 (en) 2017-06-05 2023-11-21 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
JP7557367B2 (ja) 2017-11-17 2024-09-27 アイオバンス バイオセラピューティクス，インコーポレイテッド 細針吸引及び小生検からのｔｉｌ拡大培養
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
BR112020013848A2 (pt) 2018-01-08 2020-12-01 Iovance Biotherapeutics, Inc. métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
WO2019184909A1 (zh) 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
CN112368003A (zh) 2018-04-27 2021-02-12 艾欧凡斯生物治疗公司 肿瘤浸润淋巴细胞的基因编辑及其在免疫治疗中的用途
CA3104218A1 (en) 2018-06-25 2020-01-02 Immodulon Therapeutics Limited Cancer therapy
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
CN112601761A (zh) 2018-08-13 2021-04-02 印希比股份有限公司 结合ox40的多肽及其用途
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
MX2021002887A (es) 2018-09-20 2021-06-04 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumores (tils) a partir de muestras de tumor crioconservadas.
EP3864049A1 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
CA3115089A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
JOP20210094A1 (ar) 2018-11-05 2023-01-30 Iovance Biotherapeutics Inc عمليات لإنتاج الخلايا الليمفاوية للورم الارتشاحي واستخداماتها في العلاج المناعي
BR112021008549A2 (pt) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
EP3877512A2 (en) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
EP3898949A1 (en) 2018-12-19 2021-10-27 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
MY208565A (en) 2019-02-27 2025-05-15 Ionis Pharmaceuticals Inc Modulators of malat1 expression
BR112021019328A2 (pt) 2019-03-29 2021-11-30 Myst Therapeutics Llc Métodos ex vivo para produzir um produto terapêutico de célula t e composições e métodos relacionados
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4037693A1 (en) 2019-09-30 2022-08-10 Astrazeneca AB Combination treatment for cancer
JP2022553389A (ja) 2019-10-25 2022-12-22 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用
CA3162703A1 (en) 2019-11-27 2021-06-03 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
CA3161104A1 (en) 2019-12-11 2021-06-17 Cecile Chartier-Courtaud Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
AU2021226903A1 (en) 2020-02-27 2022-10-20 Turnstone Biologics Corp. Methods for ex vivo enrichment and expansion of tumor reactive T cells and related compositions thereof
TW202208616A (zh) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 改良之腫瘤反應性ｔ細胞的選擇
US20230172987A1 (en) 2020-05-04 2023-06-08 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
US20230405114A1 (en) 2020-11-06 2023-12-21 Immodulon Therapeutics Limited Mycobacterial immunotherapy for treating cancer
WO2022101619A1 (en) 2020-11-10 2022-05-19 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy
TW202241468A (zh) 2020-12-11 2022-11-01 美商艾歐凡斯生物治療公司 用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者
EP4262827A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
WO2022133140A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
JP2024515189A (ja) 2021-04-19 2024-04-05 アイオバンス バイオセラピューティクス，インコーポレイテッド 細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用
AU2022288058A1 (en) 2021-06-07 2023-11-16 Agonox, Inc. Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
WO2023007107A1 (en) 2021-07-27 2023-02-02 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
EP4430167A1 (en) 2021-11-10 2024-09-18 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
US20250101380A1 (en) 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
CN119192303B (zh) * 2024-09-29 2025-08-12 中国人民解放军总医院 一类自组装三聚体蛋白及其制备方法
CN119390782B (zh) * 2024-09-29 2025-09-16 中国人民解放军总医院 一种自组装三聚体蛋白及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
GB9209032D0 (en) * 1992-04-25 1992-06-10 Ciba Geigy Ag New peptide derivatives
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6620413B1 (en) * 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6312700B1 (en) * 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US6828106B2 (en) * 1999-02-26 2004-12-07 Cyclacel Limited Methods and compositions using coiled binding partners
US7179468B1 (en) * 2000-06-08 2007-02-20 Cornell Research Foundation, Inc. Antigen for developing neutralizing antibodies to human immunodeficiency virus
AU2001297677B2 (en) * 2000-10-24 2007-07-05 Immunex Corporation Method for dendritic cells based immunotherapy of tumors using combination therapy
EP1355942B1 (en) * 2000-12-07 2008-08-27 Eli Lilly And Company Glp-1 fusion proteins
US7238499B2 (en) * 2001-12-21 2007-07-03 Immunex Corporation Trimeric macrophage scavenger receptor fusion proteins and encoding nucleic acids
WO2003078648A2 (en) * 2002-03-11 2003-09-25 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis

Also Published As

Publication number Publication date
US20100136032A1 (en) 2010-06-03
PT1877090E (pt) 2014-04-15
HUE029789T2 (en) 2017-04-28
AU2006244497A8 (en) 2006-11-16
SI1877090T1 (sl) 2014-12-31
EP1877090A2 (en) 2008-01-16
US20060280728A1 (en) 2006-12-14
AU2006244497A1 (en) 2006-11-16
WO2006121810A2 (en) 2006-11-16
US7959925B2 (en) 2011-06-14
PT2650020T (pt) 2016-12-12
SI2650020T1 (sl) 2017-03-31
ES2457067T3 (es) 2014-04-24
EP1877090A4 (en) 2009-07-29
EP2650020B1 (en) 2016-08-24
EP2650020A1 (en) 2013-10-16
LT2650020T (lt) 2016-12-12
AU2006244497B2 (en) 2011-09-22
CY1118504T1 (el) 2017-07-12
CA2606809C (en) 2016-01-05
ES2605380T3 (es) 2017-03-14
PL2650020T3 (pl) 2017-07-31
CA2606809A1 (en) 2006-11-16
EP1877090B1 (en) 2014-01-15
PL1877090T3 (pl) 2015-04-30
WO2006121810A3 (en) 2007-03-29
DK2650020T3 (da) 2017-01-16
CY1119342T1 (el) 2018-02-14

Similar Documents

Publication Publication Date Title
DK1877090T3 (da) Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf
DK1948852T3 (da) Hovedelektrode og fremgangsmåde til dannelse af hovedelektroden
DK1744590T3 (da) Høreapparat og tilsvarende fremgangsmåde til indstilling heraf
DK1844074T3 (da) Humane antistoffer og proteiner
DK1934179T3 (da) Fremgangsmåder og mellemprodukter
NO344992B1 (no) Anti-GM-CSF antistoffer og anvendelser for disse
DK1997291T3 (da) Metode og anordning til sikker godkendelse
DK1780295T3 (da) Svejseforbindelse og svejsemateriale deraf
DK1984344T3 (da) Multicykliske aminosyrederivater og fremgangsmåder til anvendelse heraf
DK1968429T3 (da) Fremgangsmåde og system til stabilisering af sensorer
NO20071302L (no) Bindingdomene fusjonsproteiner
DK1955102T3 (da) Fremgangsmåde og indretning til konfokal billedbehandling
DK1973429T3 (da) Proteinhydrolysater og fremgangsmåde til fremstilling
DK1871418T3 (da) Humaniserede anti-cd70-bindende midler og anvendelser deraf
DK2079355T3 (da) Fremgangsmåde og system til brilleordination
DK1745075T3 (da) Poly-n-acetylglucosamin (pnag/dpnag)-bindende peptider og fremgangsmåder til anvendelse deraf
DK1868642T3 (da) Katte-allergenfusionsproteiner og anvendelser deraf
DK1965763T3 (da) Stabile enzympræparater og fremgangsmåder til anvendelse heraf
DK2029799T3 (da) Termostabile proteiner og fremgangsmåder til fremstilling og anvendelse heraf
EP1895838A4 (en) COMPOSITIONS AND METHODS
DK2066817T3 (da) Molekylære afbrydere og fremgangsmåder til anvendelse deraf
DK1919514T3 (da) Polynucleotider kodende for isoprenoid-modificerende enzymer og fremgangsmåder til anvendelse deraf
DK2479259T3 (da) Multi-kryokonserverede hepatocytter og fremgangsmåder til fremstillilng deraf
NO20054709D0 (no) Sammenfoyningssystem og anvendelse av dette
EP1934372A4 (en) SSB-POLYMERASE HYBRID PROTEINS